{"id":"W3171912160","doi":"10.1200/jco.2021.39.15_suppl.9516","title":"Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Nivolumab; Discontinuation; Ipilimumab; Internal medicine; Clinical endpoint; Incidence (geometry); Adverse effect; Safety profile; Oncology; Gastroenterology; Randomized controlled trial; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001241419,0.0007165489,0.001377959,0.000511966,0.0003211906,0.0008443765,0.0009883554,0.001096546,0.002520048],"category_scores_gemma":[0.0009010891,0.0003847301,0.001235825,0.0003188161,0.0005115974,0.0007627463,0.00035595,0.002530881,0.0005147238],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009100396,"about_ca_system_score_gemma":0.0007284769,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001438229,"about_ca_topic_score_gemma":0.002418284,"domain_scores_codex":[0.9995925,0.000156406,0.00002747592,0.00006957081,0.00005596237,0.00009805651],"domain_scores_gemma":[0.9994424,0.00009565528,0.0001342818,0.00007795089,0.00002728222,0.000222384],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6230051,0.1196313,0.00588354,0.0007339655,0.001774196,0.0002057667,0.0003465409,0.003026019,0.05307183,0.0002750117,0.002902782,0.1891439],"study_design_scores_gemma":[0.2418319,0.721522,0.02373892,0.00004306826,0.0009659317,0.0001990999,0.00005758061,0.001624791,0.007247178,0.0001304393,0.002585748,0.00005344761],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954591,0.0019795,0.0004247332,0.0001578777,0.00009501733,0.0006358994,0.0004783603,0.00005504035,0.0007144664],"genre_scores_gemma":[0.993954,0.001192226,0.0009584589,0.000346082,0.0000924101,0.0005873173,0.0009646385,0.00001921567,0.001885627],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002520048,"threshold_uncertainty_score":0.008430421,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1008529463214198,"score_gpt":0.4533463520984132,"score_spread":0.3524934057769934,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}